Yecuris Funding: How Much Did They Raise & Key Investors

How Much Did Yecuris Raise?
Funding & Key Investors

Yecuris, a company specializing in liver-humanized mice and preclinical research services, has secured significant capital, with total funding reaching $150K. The company recently announced a major strategic investment of $150K, underscoring its advanced stage in the market. This latest financing round is expected to bolster its capabilities in gene editing, gene therapy, and infectious disease research.

What is Yecuris?

Yecuris

Business Services

Research & Development

Healthcare Services

Yecuris Corporation is a prominent provider of FRG® liver-humanized mice and associated preclinical research services. Their specialized platform is designed to accelerate drug discovery and development, particularly for conditions such as Non-alcoholic steatohepatitis (NASH), Non-alcoholic fatty liver disease (NAFLD), and viral hepatitis. By offering a high degree of physiological relevance, Yecuris aims to reduce the time and cost associated with validating novel therapeutic approaches for researchers and pharmaceutical companies.

How much funding has Yecuris raised?

Yecuris has raised a total of $150K across 1 funding round:

2020

Debt

$150K

Debt (2020): $150K with participation from PPP

What's next for Yecuris?

With the recent influx of $150K in strategic investment, Yecuris is well-positioned for its next phase of growth. This large-scale, late-stage funding suggests a focus on expanding market reach, enhancing its research service offerings, and potentially forging new partnerships within the biotechnology and pharmaceutical sectors. The company's continued innovation in preclinical models is critical for advancing therapies in complex liver diseases and infectious agents.

See full Yecuris company page

See More Financial Insights